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Background: Although medication adherence and health-related quality of life (HRQoL) are two different outcome
measures, it is believed that adherence to medication leads to an improvement in overall HRQoL. The study aimed
to evaluate the association between medication adherence and HRQoL.
Methods: A questionnaire-based cross-sectional study design was undertaken with hypertension patients attending
public hospitals in Quetta city, Pakistan. HRQoL was measured by Euroqol EQ-5D. Medication adherence was
assessed by the Drug Attitude Inventory. Descriptive statistics was used to tabulate demographic and disease-
related information. Spearman’s correlation was used to assess the association between the study variables. All
analysis was performed using SPSS 17.0.
Results: Among 385 study patients, the mean age (SD) was 39.02 (6.59), with 68.8% of males dominating the entire
cohort. The mean (SD) duration of hypertension was 3.01 ± 0.939 years. Forty percent (n = 154) had a bachelor’s
degree level of education with 34.8% (n = 134) working in the private sector. A negative and weak correlation
(−0.77) between medication adherence and EQ-5D was reported. In addition, a negative weak correlation (−0.120)
was observed among medication adherence and EQ-VAS.
Conclusions: Correlations among the study variables were negligible and negative. Hence, there is no “apparent”
relationship between the variables.
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The concepts of health-related quality of life (HRQoL) and
medication adherence are frequently used in clinical re-
search for assessing pharmaceutical care and treatment
outcomes [1]. Adherence to drug treatment usually refers
to the extent to which patients follow the instructions of
their physician or other health care providers [2]. HRQoL
is the assessment of physical, psychological and social
dimensions of health that are influenced by an individual’s
experiences, beliefs, expectations and perceptions [3]. In a
broader context, medication adherence is a transitional* Correspondence: fahaduob@gmail.com
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reproduction in any medium, provided the origoutcome variable while HRQoL is an ultimate outcome
representing conclusions following a course of care [1].
This entails that a change in adherence is likely to occur
first, which is subsequently followed by a change in
HRQoL while assessing treatment or interventional out-
comes [4]. Therefore, it can be predicted that patients who
adhere to their treatment regimen should experience
improvements in HRQoL and vice versa. Nevertheless, it
is not wise to rule out other factors affecting medication
adherence and HRQoL. For example, in the case of
chronic diseases like diabetes or hypertension, adherence
might be positively associated with side effects and per-
haps lower HRQoL. On the contrary, for acute diseases,
adherence to medication might be associated with a swift
advancement in improving HRQoL. It is now known that
in terms of quality of life, chronically ill individuals showLtd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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tion [5,6].
Within this context, hypertension is a chronic disease
that requires lifelong treatment. The success of therapy
is thereby affected by the impact of the drug regime on
the patient’s well-being [7,8]. Consequently, comprehen-
sive assessment of therapy must include assessment of
medication adherence and HRQoL along with the evalu-
ation of traditional bio-physiological measures. Antihy-
pertensive therapies should be compared for their
efficacy in controlling blood pressure and also improving
or at least maintaining HRQoL [9]. Regardless of the na-
ture of studies relating HRQoL in hypertension, it is fre-
quently reported that hypertensive patients have
decreased HRQoL [10,11]. In the presence of evidence
based guidelines [12,13], a challenge faced by the health-
care providers is that even in the “controlled state”,
hypertensive patients were reported to have decreased
HRQoL [14].
In the current literature, few studies have attempted to
measure the association between medication adherence
and HRQoL. Moreover, results from such studies provide
conflicting results [1,15-17]. This may be because of the
variations in assessing HRQoL and medication adher-
ence, as well as the study population being examined
[18]. In addition, more or less, such studies are often
produced and reported from developed nations. Consid-
ering the unavailability of information from developing
countries, the association between medication adherence
and HRQoL was examined. The aim of this study was to
examine the relationship between adherence and HRQoL
in a hypertensive population attending public hospitals
in the city of Quetta, Pakistan.
Methods
Study design
The study was designed as a questionnaire-based cross-
sectional descriptive analysis.
Settings
Two tertiary care hospitals [Sandamen Provisional Hos-
pital (SPH) and Bolan Medical Complex Hospital
(BMCH)] were approached for data collection. Both of
the institutes are teaching hospitals and are generalised
in nature, currently providing services to about 70% of
the entire city.
Ethical approval
To date, there is no ethical requirement for non-clinical
observational studies in Pakistan [19]. However, permission
to conduct the study was taken from the medical superin-
tendent of the respective institutes (EA/FS/1021-2). In
addition, written consent was also taken from the patients
prior to data collection. The patients were informed aboutthe research initiatives, confidentiality of their responses
and their right to withdraw from the study with no penalty
or effects on their treatment. In addition, the study also
received its approval from the “Post Graduate Research
Evaluation Committee” at School of Pharmaceutical
Sciences, Universiti Sains Malaysia.
Participants and sampling criteria
The National Health Survey conducted by Pakistan’s
Medical and Research Council reported that hyperten-
sion affected 18% of the adult population in Pakistan
[20]. Therefore, a prevalence-based sample of 385 hyper-
tensive patients was selected for this study [21]. As the
study was conducted in two different hospitals, 193
hypertensive patients were selected from SPH and 192
from BMCH.
Patients aged 18 years and above, with confirmed diag-
nosis of hypertension, using antihypertensive medica-
tions for the last six months and being familiar with the
national language of Pakistan (Urdu), were included in
the study. Patients aged below 18 and above 80 years,
those with co-morbidities and mental impairments, as
well as immigrants from other countries and pregnant
ladies were excluded from the study. The study was con-
ducted from July 2010 to September 2010.
Study variables and data collection
Hospital pharmacists stationed at the cardiac unit of the
respective hospitals were approached and trained by the
principal researcher for data collection. Demographic in-
formation of the study respondents was taken, as written
consent was provided by the patients for the initiation of
the study. The Drug Attitude Inventory (DAI-10) and
EuroQol quality of life scale (EQ-5D) were used to assess
medication adherence and HRQoL, respectively. DAI-10
was originally available in English and was translated into
Urdu (official language of Pakistan) by an independent
professional translator. The translation was reconfirmed
by a professor stationed at an academy of languages.
However, EQ-5D was provided by the developers in
Urdu. Both of the research instruments were tested for
reliability (Cronbach’s α being 0.70 and 0.75 for DAI-10
and EQ-5D, respectively) and validity. As the originality
and consistency of the two instruments were stabilised,
the final versions were made available to the pharma-
cists. Data from the pre-test evaluation were not
included in the final analysis.
Assessment of medication adherence
DAI-10 was originally constructed by Voruganti and Awad
[22] comprising ten items with responses in yes or no and
scores ranging from 10 to −10. Patients with scores of 6 to
10 were reported as adherent, 0 to 5 as moderately adher-
ent and those in the negative ranges as non-adherent [2].
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The EQ-5D is a generic HRQoL instrument developed by
the EuroQoL group. It consists of five dimensions that are
further divided into three levels of severity. It is a standar-
dised instrument for use as a measure of health outcome
and provides a simple descriptive profile and a single index
value for health status that can be used in the clinical and
economic evaluation of health care as well as population
health surveys [23]. The EQ-5D descriptive profile consists
of five dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression), each of which
can take one of three responses. The responses record
three levels of severity (no problems/some or moderate
problems/extreme problems) within a particular EQ-5D
dimension. The visual analogue scale (VAS) is the other
portion of EQ-5D consisting of a 20-cm health thermom-
eter with two distinct end points, the best imaginable
health state (score of 100) and the worst imaginable health
state (score of 0). This information can be used as a quan-
titative measure of health outcome as judged by the indi-
vidual respondents.
Statistical analysis
Descriptive statistics were used to describe demographic
and disease characteristics of the patients. Percentages
and frequencies were used for the categorical variables,
while means and standard deviations were calculated for
the continuous variables. The characteristics of the
whole sample, medication adherence scores and HRQoL
were presented.
EQ-5D was scored using values derived from the UK gen-
eral population survey reported in 1995 [24]. Medication
adherence was calculated using the criteria originated by
the developers [22,25]. Spearman’s rank correlation test was
used to measure the association between medication adher-
ence and HRQoL. All analyses were performed using SPSS
version 17.0 (SPSS Inc., Chicago, IL).
Results
Table 1 reflects the demographic characteristics and
HRQoL scores among the study participants. Among
the 385 study patients, the mean age (SD) was 39.02
(6.59) years, with 68.8% of males dominating the entire
cohort. The mean (SD) duration of hypertension was
3.01 ± 0.939 years. Forty percent (n = 154) had a bache-
lor’s degree level of education with 34.8% (n = 134)
working in the private sector. Almost 41% (n = 140) had
a monthly income of more than 15000 Pakistan rupees
(Pk Rs) [1 Pk Rs = 0.01172 $US] with 75.1% (n = 289)
having an urban residency.
The mean EQ-5D descriptive score was 0.46 ± 0.28 and
EQ-VAS score was 63.97 ± 6.6. A total of 29 different
EQ-5D health states were described by the patients
(Table 2). The majority of the participants (n=112, 29.1%)reported their health status (21122) indicating no problem
in the second and third domain, while moderate problem in
the first, fourth and fifth domain (mobility “first”, self-care
“second”, usual activities “third”, pain/discomfort “fourth”
and anxiety/depression being the “fifth” domain). There was
not a single patient who stated no problem in all five
domains as shown in Table 2. Interestingly, poor treatment
adherence (−1.89) was reported in the most frequent
reported heath status. Moreover, participants with best
health status (11112) among the study cohort reported the
worst treatment adherence (−4.0).Adherence scores
The responses of patients to the DAI-10 scale are pro-
vided in Table 3. DAI-10 test scores ranged between 10
and −10 with the overall mean score of −1.74 ± 2.154
and median score of −2. Out of the 385 patients, 249
(64.7%) were categorised as poorly adherent and 136
(35.3%) as moderately adherent to their therapies. No pa-
tient was considered to be adhering well to their medica-
tion. Poor adherence was apparent in responses to
questions 9, 5 and 2 where correct answers constituted
4.9, 15.6 and 30.4%, respectively. The correct answers
were highest in response to questions 6 and 7, which
were 93.0 and 76.9%, respectively.
The Spearman’s rank order correlation coefficient be-
tween total adherence and EQ-5D scores was −0.77 and
total adherence and EQ-VAS scores −0.120 (Table 4).
Therefore, the current study findings indicate an inverse
association between the included study variables. No sig-
nificant difference was observed between the current
study variables.Discussion
The results from the present study show a weak or neg-
ligible negative correlation between medication adher-
ence and HRQoL. The participants were also reported
with decreased HRQoL and poor treatment adherence
to medications. Similar results were reported in a meta
analysis where hypertension patients were reported with
decreased HRQoL [10]. In another study among hyper-
tensive patients, lower medication adherence was asso-
ciated with poor HRQoL in a population based survey
in Brazil [14].
With the exception of the negative association, the
current study findings agree with those in the literature
[1,16,26,27]. However, Carbello et al. concluded that
certain HRQoL domains are closely related to medica-
tion adherence in an HIV population [28]. These find-
ings were again supported by Takemura and colleagues,
who concluded that better adherence is associated with
better HRQoL in their study among asthmatic patients
in Japan [29].
Table 1 Characteristics of survey respondents and description of HRQoL scores










18-27 48 (12.5) 0.5913 0.18401 66.81 5.652
28-37 186 (48.3) 0.5007 0.25706 64.68 5.862
38-47 128 (33.2) 0.4104 0.31491 59.87 7.160
>48 23 (6.0) 0.2576 0.28444 63.97 6.621
Gender
Male 265 (68.8) 0.4677 0.28194 64.03 6.466
Female 120 (31.2) 0.4669 0.29107 63.84 6.978
Education
Illiterate 9 (2.3) 0.2543 0.33554 59.44 6.521
Religious 62 (16.1) 0.3005 0.34637 60.63 6.744
Primary 7 (1.8) 0.5583 0.18048 63.57 2.992
Matric 51 (13.2) 0.4371 0.28744 64.59 7.245
Intermediate 51 (13.2) 0.5231 0.25906 65.06 5.774
BA/BSc 154 (40.0) 0.5293 0.23171 64.84 6.130
Masters 51 (13.2) 0.4835 0.28105 64.59 7.119
Occupation
Jobless 97 (25.2) 0.4337 0.29882 63.24 7.077
Government official 78 (20.3) 0.4796 0.27688 64.44 7.011
Private Job 134 (34.8) 0.5295 0.23761 65.16 5.503
Businessman 76 (19.7) 0.3886 0.32602 62.36 7.080
Income
Nil 97 (25.2) 0.4337 0.29882 63.24 7.077
< Pk Rs 5000 2 (0.5) 0.4210 0.33234 65.00 7.071
5000-10000 22 (5.7) 0.5628 0.19853 65.68 6.549
10000-15000 104 (27.0) 0.5231 0.23856 65.25 5.841
> 15000 160 (41.6) 0.4392 0.30643 63.34 6.735
Locality
Urban 289 (75.1) 0.5113 0.25466 64.97 6.156
Rural 96 (24.9) 0.3356 0.32713 60.98 7.089
Duration of disease (3.01 ± 0.939)
Less than 1 year 26 (6.8) 0.5885 0.18203 67.04 4.976
1-3 years 89 (23.1) 0.5158 0.25582 65.33 6.335
3-5 years 124 (32.2) 0.4738 0.26777 64.35 6.106
> 5 years 146 (37.9) 0.4110 0.31733 62.28 7.074
Total Sample 385 0.4674 0.28444 63.97 6.621
The mean HRQoL score was 46.74 ± 28.44 with VAS score 63.97 ± 6.621 indicting poor status of life in our study respondents.
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ence and HRQoL is explainable using the theoretical
model of Self-Regulation [30]. Interest and involvement
of patients in improving one's own health is the key de-
terminant of a successful medical treatment. Medication
adherence is an important component of disease state
management; however, it is one phase of the entire
process. HRQoL, on the other hand, encircles a complexweb of psychosocial characteristics that can impact a
patient’s ability to manage their chronic disease and does
not depend on a single factor. In the majority of cases,
the patient observes their own behaviour and evaluates
how this behaviour affects their current health status.
Only if the desired results are not realised, a change in
personal behaviour is initiated. If the patients are satis-
fied with the outcomes, they maintain status quo. A
Table 2 Frequency of self-reported (EQ-5D) Health States































Within 29 different health states, majority (n = 112, 29.1%) stated moderate
difficulty in the first, fourth mad fifth domain respectively, where as they stated
no difficulty in the second and third domain*.
* [(Mobility, self-care, usual activities, pain/discomfort and anxiety/depression)
Domains of HRQoL in order].
Table 3 Drug Adherence Data




For me, the good things about
medication outweigh the bad.
58.4 41.6
I feel uncomfortable on medication. 69.6 30.4
I take medications of my own choice. 40.3 59.7
Medications make me feel more relaxed. 60.3 39.7
Medication makes me feel tired and sluggish. 84.4 15.6
I take medication only when I am sick. 93.0 7.0
I feel more normal on medication. 76.9 23.1
It is unnatural for my mind and body to be
controlled by medications.
40.0 60.0
My thoughts are clearer on medication. 4.9 95.1
By staying on medications,
I can prevent getting sick.
60.0 40.0
My thoughts are clearer on medication. 4.9 95.1
By staying on medications,
I can prevent getting sick.
60.0 40.0
Adherence was assessed by giving 1 to correct answer and −1 to the wrong
answer. The scale measured adherence from a maximum of 10 to a minimum of
−10. Any negative score was rated as non adherence, 0–5 as moderate adherence
and 6–10 as adherent. Mean adherence was −1.74 ± 2.15.
Table 4 Correlation coefficient (Total adherence score and
EQ-VAS score)
Spearman’s Rho Adherence score EQ-VAS score EQ-5D Score
Correlation Coefficient 1.000 -0.120 -0.77
Sig. (2-tailed)* - 0.169 0.132
N 385 385 385
*Correlation significant at the 0.05 level.
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the recognition that HRQoL is affected by a number of
factors and is not limited to medication adherence only.
A possible explanation of this negative association can
be attributed to the measurement of medication adher-
ence and HRQoL. Although there is no “gold standard”
for adherence and HRQoL measurement [31,32], it is al-
ways advisable to use a disease/population specific in-
strument. This can result in a response to small changes
in medication adherence and HRQoL and perhaps can
give a stronger association. Even though Cote et al. used
four different instruments of HRQoL assessment
(RAND-12, SF-12, HUI-2 and HUI-3) and the MoriskyMedication Adherence Scale (MMAS) for assessing
medication adherence, proposed a disease-specific in-
strument, which is in line with our suggestions [1].
The negative association that was observed here may be
linked to the frequency and class of antihypertensive medi-
cation used by the patients. The efficacy of antihyperten-
sive agents is unquestionable but certain side effects are
always associated with the therapy [33,34]. Side effects in
“adherents” can be one possible reason for the decreased
HRQoL. Moreover, different antihypertensive agents affect
HRQoL in a different way. Even medications from the
same pharmacological class, with the same efficacy and
safety profile, show different impact on HRQoL [7]. For
example, a study involving two different calcium channel
blockers, nifedipine and amlodipine, concluded that nifedi-
pine had a positive effect on overall quality of life com-
pared with no change in the amlodipine group [35].
In this context, the duration of the disease itself is very
important in interpreting the association between medi-
cation adherence and HRQoL. Patients who are recently
diagnosed with hypertension may experience an
increased HRQoL for the first few months of therapy.
However, for chronic hypertensive patients, adherence to
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HRQoL in chronic patients can be observed as “main-
tained” but this preservation is never taken as
“improved” by the patients. This is supported by the
current study results, where 146 (37.9%) and 124 (32.3%)
of the respondents had hypertension for more than five
years and within three to five years, respectively, and
reported decreased HRQoL.
The current findings revealed that the study cohort
was dominated by age group of 28–37 years (48.3%) and
patients with bachelor’s level of education (40.0%). How-
ever, both treatment adherence and HRQoL are multi–
factor phenomenon and success or failure of therapy and
overall health status are not dependent on a single factor
[2,3]. Factors such as gender, low socioeconomic status,
prescribed drugs, posology, lack of social support, poor
patient provider relationship, cost, forgetfulness, and
presence of psychological problems should also be kept
in mind and evaluated before coming to a conclusion
regarding treatment adherence and its effect on HRQoL.
Conclusion
In general, the weak correlation between medication ad-
herence and HRQoL reflects no “apparent” relationship.
The absence of an association indicates other factors
affecting HRQoL during the course of care. Further
investigations of the relationship between medication ad-
herence and HRQoL using disease-specific instruments
are warranted.
Limitations
This study has some limitations. Patients with co-
morbidities were excluded from the study as the
current study was conducted at a remote place with
no available database. Co-morbidities, however, can
modify adherence behaviour in patients as well as
HRQoL. In addition, adherence was assessed by self-
reported method. The use of other tools like pill
counts or electronic monitoring can give sensitive
results, but it is not possible to employ such methods at
present as the area lacks basic infrastructure. In addition,
the results were drawn from one city and cannot be gener-
alised to the entire country.
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